
AstraZeneca’s Breztri Meets Primary Endpoints in Duo of Phase III Asthma Trials
AstraZeneca has announced positive results from the Phase III KALOS and LOGOS clinical trials of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) in patients with uncontrolled asthma. The fixed-dose, triple-combination therapy met …